Eiger Biopharmaceuticals

Eiger BioPharmaceuticals is a clinical stage biopharmaceutical company focused on bringing to market product candidates for the treatment of rare diseases. The company's product candidate pipeline includes four programs: Lonafarnib (LNF) in Hepatitis Delta Virus (HDV), which is an orally bioavailable, farnesylation inhibitor in Phase 3 clinical trials for HDV infection; Peginterferon Lambda in HDV, which is a late-stage, type III interferon that stimulates immune responses; LNF in Progeria and Progeroid Laminopathies (PL), which the company develops LNF for treatment of PL; and Avexitide in Post-Bariatric Hypoglycemia (PBH), which is a peptide that the company is developing as a treatment for PBH.
  • TickerEIGR
  • ISINUS28249U1051
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Wedbush Research

Wedbush Morning Call - Jul 13 2020 6:44AM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 29 2020 6:40AM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 22 2020 6:30AM

3 directors bought/maiden bought

Three Directors at Eiger BioPharmaceuticals Inc bought/maiden bought 7,250 shares at between 11.030USD and 11.099USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is...

Wedbush Research

Wedbush Morning Call - Jul 13 2020 6:44AM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 29 2020 6:40AM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 22 2020 6:30AM

ResearchPool Subscriptions

Get the most out of your insights

Get in touch